4D MOLECULAR THERAPEUT

4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

01 Jun 2023 07:00:01 By Nasdaq GlobeNewswire

4DMT to Present Interim Data from 4D-710 Phase 1/2 AEROW Clinical Trial for Cystic Fibrosis Lung Disease at the European Cystic Fibrosis Society (ECFS) 46th Annual Meeting

24 May 2023 07:00:01 By Nasdaq GlobeNewswire

4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

11 May 2023 07:00:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports First Quarter 2023 Financial Results and Operational Highlights

10 May 2023 15:05:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

09 May 2023 15:05:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in Upcoming Investor Conferences

08 May 2023 15:05:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

04 May 2023 20:04:59 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock

04 May 2023 15:08:59 By Nasdaq GlobeNewswire

4DMT Presents Positive Interim Data from Intravitreal 4D-150 Phase 1/2 PRISM Clinical Trial in Patients with Wet AMD at ARVO 2023

27 Apr 2023 06:00:01 By Nasdaq GlobeNewswire

4DMT Acquires Complement Pathway Inhibitor Payload for 4D-175 Product Candidate for Geographic Atrophy

24 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

4DMT to Present Interim Data from 4D-150 Phase 1/2 PRISM Clinical Trial for Wet AMD at ARVO 2023, and Promotes Robert Kim, M.D. to Chief Medical Officer

13 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Full Year 2022 Financial Results and Operational Highlights

15 Mar 2023 15:05:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials & Development Plans for Fabry Disease Cardiomyopathy at WORLDSymposium™

22 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

4DMT to Present Interim Clinical Data from INGLAXA Phase 1/2 Trials of 4D-310 for Fabry Disease Cardiomyopathy at 19th Annual WORLDSymposium™

16 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the SVB Securities Global Biopharma Conference

08 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces FDA Clearance of IND Application for 4D-150 Genetic Medicine for the Treatment of Diabetic Macular Edema

02 Feb 2023 15:05:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics to Participate in the Upcoming Evercore ISI HealthCONx 2022 Conference

21 Nov 2022 15:05:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Announces Interim Clinical Data from On-going Phase 1/2 Clinical Trial of Intravitreal 4D-150 for Wet Age-Related Macular Degeneration (wet AMD)

14 Nov 2022 06:30:00 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Interim Clinical Data from the On-going Phase 1/2 Clinical Trial of 4D-150 for Wet AMD to be Released Monday, November 14, 2022

10 Nov 2022 15:05:01 By Nasdaq GlobeNewswire

4D Molecular Therapeutics Reports Third Quarter 2022 Financial Results

09 Nov 2022 15:05:02 By Nasdaq GlobeNewswire